

2020 IMPACT REPORT



Lung
Foundation
Australia
Celebrating 30 Years



2020 Prime Awards
NGO of the Year

Hope in every breath

Georgia, 49, is a mother of two. It was December 2019 when she was told she had just six months to live. She would never see her children graduate.

“I’d been going to my GP for two years saying I was tired, and we just put it down to work and looking after children,” Georgia says.

“I mentioned to my GP that I’d blown my nose and there was a tiny bit of blood. I didn’t think anything of it ... I had basically been at a spin class, and I was running around and doing lots of long-haul flights.”

The lung cancer diagnosis was shattering.

“The shock and disbelief was incredible. I was sobbing for six months into my journey...the confusion, anxiety and fear were debilitating.

“Thankfully a progressive medical team has facilitated an initial death sentence into living with the disease and having it managed as a chronic illness.”

Georgia says being asked if she could afford to pay for “life-saving, game-changing” tests and medication was difficult to comprehend. The genomic testing she needed was only available overseas and left Georgia and her family thousands of dollars out of pocket, but it was a small price to pay for more precious time together.

“It was life-changing. I hope that through further investment in research here in our own country, every Australian touched by lung disease or lung cancer will have access to the best treatment and care.

“It has given me hope, not only to spend time with my family, but also to get back to work, which is more than I could’ve ever possibly asked for two years ago when I was diagnosed.”

Front cover: Georgia, living with lung cancer, and her daughter Bonnie, brother Patrick, and father Stephen. Image credit: Izzy Dalliston

Pictured: Georgia and her daughter Bonnie. Image credit: Izzy Dalliston

About Lung Foundation Australia

Lung Foundation Australia is the only charity and leading peak body of its kind in Australia that funds life-changing research and delivers support services that give hope to Australians like Georgia.

Since 1990, we have been working to ensure lung health is a priority for all, from promoting lung health and early diagnosis, advocating for policy change and research investment, raising awareness about the symptoms and prevalence of lung disease and championing equitable access to treatment and care.

Our Vision

Lung Foundation Australia enables life-saving lung health and lung cancer research, and champions programs so that Australians with lung disease and lung cancer can live their best life.

Our Mission

By 2030, Lung Foundation Australia will be recognised as one of the world’s most innovative and effective lung health charities and a fearless leader of lung health and lung cancer policy, programs and research.

Our Values

Bold | be proactive and take risks that achieve our Mission.

Entrepreneurial | be focused on outcomes.

Fair | be equitable and work in the interests of all our stakeholders, particularly patients and their carers.

Agile | create positive change.

Innovative | be inventive to achieve our Mission.

Respectful | be honest and work hard every day in every way – we are funded by the community, they should expect nothing less.

Supporters and Partners

We thank the individual donors, community fundraisers, Commonwealth and State Governments, trusts, foundations, and corporate or supporting partners for their contribution to Lung Foundation Australia’s work in 2020. Our Mission would not be possible without you.

For information about Lung Foundation Australia, including our Board and staff, governance and partners, please visit lungfoundation.com.au.

Acknowledgement of Country

Lung Foundation Australia acknowledges Australia’s First Nations People and pay our respect to Aboriginal and Torres Strait Islander Elders, past, present and emerging. We do so in a spirit of reconciliation recognising that Aboriginal and Torres Strait Islander people across Australia are significantly over-represented in lung disease and lung cancer. We commit to partnering with communities to address this and Close the Gap.

Welcome

On behalf of the Board of Directors we are delighted to present this interim Impact Report for the year ending 31 December 2020. As Lung Foundation Australia celebrated 30 years of promoting healthy lungs and giving hope to Australians living with lung disease and lung cancer, 2020 was perhaps the most challenging in our charity's history.

The national bushfire emergency, floods and the COVID-19 pandemic placed an enormous strain on our resources and capacity, as we worked to keep pace with the surge in demand for information and support. As Australia's oldest and most trusted lung disease and lung cancer charity, Australians turned to us for information in record numbers. COVID-19 as a respiratory disease, together with the breathlessness caused by bushfire smoke, has given all Australians cause to rethink the importance of their and their family's lung health.

Our wonderful community of patients, families, consumer committee members and patient advocate groups worked tirelessly with staff to ensure our community, though isolated in person, remained connected, informed and safe. It is testimony to the incredible resilience of people living with lung disease and lung cancer that our services thrived, despite necessary lockdowns, and more people connected with Lung Foundation Australia than ever before.

Our lung health and COVID-19 digital hub was recognised internationally as a trusted source of information. Throughout the year our digital lung health strategy enabled us to open our services to new communities. The Maintaining Movement exercise series and peer support network went digital; the Chronic Obstructive Pulmonary Disease (COPD) Texting for Wellness SMS service was launched; our patient webinar series set new records for attendance; and 61 new resources for health professionals and patients, including the COPD-X Concise Guide, were launched. Whilst 90% of community and fundraising events were cancelled, including our 30th Anniversary Gala Dinner, Lung Foundation Australia's virtual fundraising, such as Challenge 30, proved to be an enormous success, as were our annual appeals which recorded strong growth.

The organisation's staff transformed our services overnight while continuing to press governments to do better for the lung health of Australians – equitable research funding; more dedicated specialist nurses; funding for new life-saving drugs and treatments; and importantly, earlier diagnosis through improved education and awareness.

We celebrate our work in tobacco and health policy, having secured funding for the National Vaping and Young People Roundtable and then the nib Foundation's People's Choice Award to develop new resources to educate young people about vaping and lung health.



Chairperson
Professor Christine
Jenkins AM and CEO
Mark Brooke.

The Board thanks and acknowledges Lung Foundation Australia's senior leadership and staff for their incredible contribution. They truly exemplify our values; bold, innovative, agile and entrepreneurial. Despite the challenges of COVID-19 they continued all programs. We are excited and pleased to announce that \$8 million was raised or pledged for our Hope Research Fund, well ahead of our first-year target. The Board has set an ambitious goal of raising \$50 million in the next 10 years for lung disease and lung cancer research and we are off to a very strong start. The Hero for Hope campaign for Pulmonary Fibrosis (PF) and rare lung disease research achieved its target, raising \$1.6 million well ahead of schedule. This funding will be allocated to world-leading research and translational projects, in partnership with the Pulmonary Fibrosis Australasian Clinical Trial Network and the Centre of Research Excellence in Pulmonary Fibrosis.

Amongst the many highlights was the securing of new Commonwealth funding for our Lungs in Action program, Occupational Lung Disease (OLD) and Chronic Cough programs, and support from the Queensland Government to expand our Information and Support Centre service.

We were honoured to receive the 2020 PRIME Award for Non-Government Organisation of the Year. The Lung Cancer Search and Rescue Campaign was also acknowledged for best use of data and insights in a consumer health promotions campaign. Our organisational culture and the safety of our people remains a strategic priority and this was recognised with the receipt of a Your Voice Project Best Workplace Award for 2020. Whilst we don't seek these accolades, they give us confidence that Lung Foundation Australia will be here for another 30 years.

In 2020, Lung Foundation Australia was accredited under the Government's Health and Community Service Standards. This should give members a great deal of comfort that our governance and operational systems reflect a modern charity as well as an efficient and effective profit for purpose organisation.

Looking forward, Lung Foundation Australia will face a number of challenges in the years ahead including:

- Increased pressure on our research budget as university investment is anticipated to decline and government research investment remains very competitive.
- Keeping our community connected and sustaining our community programs as they adjust to the new normal caused by the continuing disruptions of COVID-19.
- Partnering with government, health services and the community to promote the importance of vaccinations, including the COVID-19 vaccine.
- Keeping health professionals aware of and utilising Lung Foundation Australia's resources to enhance patient care, education and self-management.
- Prosecuting and progressing greater investment in lung disease and lung cancer specialist nurses and equity of research investment.
- Taking the opportunity created by Australia's renewed focus on lung health to raise and invest funds against a backdrop of economic uncertainty.
- Ensuring our workplaces, programs and staff are kept safe and well.

We finish with a message of thanks to the 300-plus health professionals and researchers who partner with us. They freely give their time and expertise and, in 2020, they pivoted quickly to address the issues raised by the pandemic for people with lung disease. Their commitment also ensured that our support and research activities continued in lung cancer, Interstitial Lung Diseases, PF, COPD, bronchiectasis and OLD.

Finally, our thanks to you for answering our call for support and donating your time, expertise and money throughout the past 12 months. Your support is critical to enabling us to provide the very best information and support, and advocate for equitable access to treatment, care and support for every Australian impacted by lung disease or lung cancer.

Professor Christine Jenkins AM
Chairperson

Mark Brooke
Chief Executive Officer

Our 2020 impact

Thanks to the generosity of donors, fundraisers and bequestors, Lung Foundation Australia's resources, information, programs and services reached thousands of Australians in 2020.

With your support we have continued our mission to make lung health a priority for all Australians and to ensure every Australian impacted by lung disease or lung cancer has access to the treatment, care and support they deserve.

"Research to us means the world. It gives families such as ours and all families caring for someone with lung disease hope."

Georgie, Eve's Mother.

Supporting patients and carers



61 new webinars, fact sheets and resources developed and delivered.

965,590 website visits providing resources and support to patients, carers and health professionals.



3,000+ health-related enquiries to our Information and Support Centre.

"Lung Foundation Australia was a huge help while I was dealing with my lung condition. They were always there to answer any questions and the resources and support options were all beneficial."

- Sandy, lives with lung cancer.

Driving lung health policy changes



40+ patient voice-led submissions made to improve access to medications and services.



Queensland Government promised to explore a specialist lung cancer nurse trial.



4 recommendations delivered from the National Strategic Action Plan for Lung Conditions.



200+ consumer-led presentations to state and federal politicians to drive reform.



Led the National Vaping and Young People Roundtable.

Increasing research investment

\$2 million

invested in lung health research including 17 fellowships and scholarships.



21 research institution funding application partnerships.

\$8 million

raised or pledged to our Hope Research Fund.

"It was always my intention to leave a proportion of my Will to a charity that I felt comfortable with. Once I became a member of the Lung Foundation it was a natural fit."

- Lynda.

Raising the profile of lung health



2 national, award-winning campaigns addressed symptom awareness and support for patients.



21,000+ people accessed our online Lung Health Checklist.

5,055+ media articles about lung health reached

1.46+ billion people.



PRIME Awards
NGO of the Year for 2020.

Supporting best-practice patient care and support



Convened the COVID-19 Expert Working Group with 7 leading respiratory, oncology and infectious disease experts.

28,800+

clinical tools and resource downloads including the new COPD-X Concise Guide for health professionals, Bronchiectasis Action Plan and Stepwise Management of Stable Bronchiectasis.

2,500+

health professionals from 22+ countries registered for our virtual education sessions.



Eve and her mother Georgie.

Helping our community navigate the pandemic

Working closely with our COVID-19 Expert Working Group, Lung Foundation Australia collated the latest information and developed an extensive range of practical resources and tools to support our vulnerable patient community through the COVID-19 pandemic. This internationally recognised and trusted information helped the community protect themselves against the virus and navigate the unique challenges of isolation.



62%

increase in website traffic during the peak of the pandemic.



134,000+

visits to our digital COVID-19 resources and information.



19

new resources and webinars to support the physical and mental wellbeing of patients, carers and families.

"Thank you for the COVID-19 information. I didn't know which information to believe but now feel much more confident."

– Sandra, lives with lung disease.



Lung Foundation Australia's Respiratory Care Nurse, Amanda.

Financials

On behalf of the Board's Finance, Audit and Risk Management (FARM) Committee, I am pleased to provide an overview of Lung Foundation Australia's financial results for the period ending 31 December 2020.

Despite the considerable and ongoing challenges faced by Lung Foundation Australia brought about by the COVID-19 pandemic and the associated disruptions to fundraising and events, the Foundation achieved a surplus of \$2,730,490 compared to \$289,009 in the previous year (an increase of 945%). The Foundation's balance sheet strengthened considerably as Equity increased to \$5,335,010 compared to the previous year \$2,372,738 (an increase of 225%).

Coinciding with Lung Foundation Australia's 30th Anniversary celebrations, a research corpus, the Hope Research Fund, was established and a total of \$5,813,801 was set aside for lung disease and lung cancer research. This positive financial result was aided by increased Commonwealth, State and philanthropic grants; assistance via the Federal Government's Job Keeper subsidy; increased donations, major gifts and bequests, and expenditure restraint in administration and non-essential areas.


I am pleased to report core activities of patient support, clinical programs and research were maintained and/or increased in 2020. As a consequence of the COVID-19 pandemic the FARM Subcommittee determined to meet monthly and oversaw a range of Board and management initiated reforms, including improved cash flow forecasting and reporting; the appointment of and transition to a new Investment Advisor - Perpetual Trustees; the selection of and provision for a new financial management and reporting system to accommodate for future growth; and two independently conducted Staff Engagement Surveys to gauge health, safety and workplace culture throughout the pandemic.

We thank our donors, supporters and partners for their assistance throughout the year.

Mr Andrew Churchill
FARM Subcommittee Chair



- Health Programs (34%)
- Research (26%)
- Awareness/Advocacy (17%)
- Fundraising (9%)
- Admin, Governance, Compliance (14%)



- COPD (24%)
- Lung Cancer (33%)
- Pulmonary Fibrosis (33%)
- Rare Lung Diseases (10%)



- Corporate (27%)
- Donations (14%)
- Bequests (26%)
- Government (24%)
- Other Revenue (4%)
- Investment Income (2%)
- Sales (1%)
- Events (2%)

Lung Foundation Australia statement of profit or loss and other comprehensive income

For the year ended 31 December 2020

	2020 [\$]	2019 [\$]
Continuing operations		
Grants - Government	1,239,424	1,010,586
Grants - other sources	393,831	319,982
Sponsorships	1,855,405	2,869,985
Donations	1,148,820	1,211,381
Bequests	2,332,470	622,547
Events	137,875	308,058
Revenue from specifically designated funds	191,939	293,837
Other income	1,518,524	591,427
Total revenue and other income from continuing operations	8,818,288	7,227,803
Research expenses	(1,403,443)	(1,661,651)
Programs and services expenses	(997,402)	(1,546,722)
Employee Expenses	(2,838,641)	(2,696,621)
Fundraising expenses	(158,583)	(278,707)
Marketing expenses	(214,485)	(325,707)
Other expenses	(503,283)	(449,936)
Surplus / (deficit) from continuing operations before finance income	2,702,451	268,459
Finance income	28,039	20,550
Net surplus / (deficit)	2,730,490	289,009
Other comprehensive income		
Items that may be reclassified subsequently to profit or loss:		
Fair value gains/(losses) on Equity FVOCI financial assets	315,934	160,623
Total comprehensive income / (loss)	3,046,424	449,632
Net surplus / (deficit) for the year is attributable to:		
Members	2,730,490	289,009
	2,730,490	289,009
Total comprehensive income / (loss) for the year is attributable to:		
Members	3,046,424	449,632
	3,046,424	449,632

Lung Foundation Australia statement of financial position

As at 31 December 2020

	2020 [\$]	2019 [\$]
Current assets		
Cash and cash equivalents	1,334,516	1,776,409
Receivables	528,274	749,347
Financial assets - Hope Research Fund	-	295,353
Financial assets - Company	1,161,008	447,750
Total current assets	3,023,798	3,268,859
Non-current assets		
Financial assets - Hope Research Fund	5,813,801	480,417
Financial assets - Company	76,756	1,764,284
Property, plant and equipment	153,621	193,496

Right of Use Asset	569,676	711,431
Intangible assets	-	175,362
Total non-current assets	6,613,854	3,324,991
Total assets	9,637,652	6,593,850
Current liabilities		
Payables	222,018	219,094
Income in advance	2,426,641	1,631,596
Contract liability	838,425	1,465,631
Lease liabilities	214,422	199,230
Employee benefits	139,127	122,323
Total current liabilities	3,840,633	3,637,874
Non-current liabilities		
Payables	-	-
Lease liabilities	403,829	545,353
Employee benefits	58,180	37,885
Total non-current liabilities	462,009	583,238
Total liabilities	4,302,642	4,221,112
Net assets	5,335,010	2,372,738
Equity		
Retained earnings	5,040,276	2,309,786
Equity FVOCI financial assets reserve	294,734	62,952
Total equity	5,335,010	2,372,738

Lung Foundation Australia statement of cash flows

For the year ended 31 December 2020

	2020 [\$]	2019 [\$]
Cash flows from operating activities		
Receipts from operating activities from government	1,239,454	1,010,586
Receipts from operating activities (except government grants)	8,615,912	6,731,547
Payments for operating activities	(6,287,296)	(7,802,148)
Dividends received	130,974	126,612
Interest received	29,313	36,591
Interest paid	(39,863)	(45,954)
Net cash flows from operating activities	3,688,494	57,234
Cash flows from investing activities		
Proceeds from term deposits	10,929	451,205
Acquisition of securities and equities	(6,730,640)	(217,591)
Proceeds from sale of securities and equities	2,837,242	282,330
Acquisition of plant and equipment	(23,077)	(131,623)
Acquisition of intangible assets	-	(71,298)
Net cash flows used in investing activities	(3,905,546)	313,023
Cash flows from financing activities		
Payment of finance lease liabilities (principal)	(224,841)	(165,502)
Net cash flows used in financing activities	(224,841)	(165,502)
Net increase/(decrease) in cash and cash equivalents held	(441,893)	204,755
Cash and cash equivalents at the beginning of the financial year	1,776,409	1,571,654
Cash and cash equivalents at the end of the financial year	1,334,516	1,776,409

How you can support us

Leaving a Legacy



Naming Lung Foundation Australia in your Will is an act of generosity that proclaims your commitment to future generations of people impacted by lung disease and lung cancer. A gift in your Will does not have to be large for it to be valuable and give hope to others.

Give a regular gift



Understanding the causes and future treatment of lung disease and lung cancer requires a long-term approach. Regular donors give Lung Foundation Australia a reliable and sustainable stream of donations which help us plan well into the future. A donation of even \$5.00 per week goes a long way and allows great science to flourish.

Become a member



Lung Foundation Australia membership is not required to access any information or services offered by the organisation. However, your membership will provide us with much needed ongoing support, and in return you will join a community of health professionals, researchers and patients all striving to improve care for the seven million Australians living with lung disease and lung cancer.

Philanthropy & partnerships



We are proud to partner with philanthropists, companies, trusts and foundations to raise vital funds for lung disease and lung cancer research. We are outcomes focused and ensure your investment can be tracked against measurable goals, and we will keep you up to date on our progress.



Level 2, 11 Finchley Street MILTON QLD 4064

PO Box 1949 MILTON QLD 4064

enquiries@lungfoundation.com.au

lungfoundation.com.au

Free call 1800 654 301



Voice Project Workplace of the Year



This report was printed on EcoStar 100% recycled paper.